使用神经导航引导聚焦超声对胶质母细胞瘤患者进行超声活检的首例人体前瞻性试验。
First-in-human prospective trial of sonobiopsy in glioblastoma patients using neuronavigation-guided focused ultrasound.
作者信息
Yuan Jinyun, Xu Lu, Chien Chih-Yen, Yang Yaoheng, Yue Yimei, Fadera Siaka, Stark Andrew H, Schwetye Katherine E, Nazeri Arash, Desai Rupen, Athiraman Umeshkumar, Chaudhuri Aadel A, Chen Hong, Leuthardt Eric C
出版信息
medRxiv. 2023 Mar 18:2023.03.17.23287378. doi: 10.1101/2023.03.17.23287378.
Sonobiopsy is an emerging technology that combines focused ultrasound (FUS) with microbubbles to enrich circulating brain disease-specific biomarkers for noninvasive molecular diagnosis of brain diseases. Here, we report the first-in-human prospective trial of sonobiopsy in glioblastoma patients to evaluate its feasibility and safety in enriching circulating tumor biomarkers. A nimble FUS device integrated with a clinical neuronavigation system was used to perform sonobiopsy following an established clinical workflow for neuronavigation. Analysis of blood samples collected before and after FUS sonication showed enhanced plasma circulating tumor biomarker levels. Histological analysis of surgically resected tumors confirmed the safety of the procedure. Transcriptome analysis of sonicated and unsonicated tumor tissues found that FUS sonication modulated cell physical structure-related genes but evoked minimal inflammatory response. These feasibility and safety data support the continued investigation of sonobiopsy for noninvasive molecular diagnosis of brain diseases.
超声活检是一种新兴技术，它将聚焦超声（FUS）与微泡相结合，以富集循环中的脑疾病特异性生物标志物，用于脑部疾病的无创分子诊断。在此，我们报告了胶质母细胞瘤患者超声活检的首例人体前瞻性试验，以评估其在富集循环肿瘤生物标志物方面的可行性和安全性。使用与临床神经导航系统集成的灵活FUS设备，按照既定的神经导航临床工作流程进行超声活检。对FUS超声处理前后采集的血样分析显示，血浆循环肿瘤生物标志物水平有所提高。对手术切除肿瘤的组织学分析证实了该操作的安全性。对超声处理和未超声处理的肿瘤组织进行转录组分析发现，FUS超声处理调节了与细胞物理结构相关的基因，但引发的炎症反应最小。这些可行性和安全性数据支持继续研究超声活检用于脑部疾病的无创分子诊断。
Zotero 插件